ARTICLE | Financial News
Entrada raises $59M series A to take intracellular biologic into clinic
December 18, 2018 1:00 PM UTC
Entrada Therapeutics Inc. (Boston, Mass.) emerged from stealth Tuesday after raising $59 million in a series A round intended to propel its first intracellular biologics program into clinic.
Intracellular targets have proven challenging for small molecules and antibodies alike; small molecules require a defined, hydrophobic binding pocket, and antibodies cannot cross the cell's lipid bilayer (see "Breaking the Barrier")...